KROS FY 2021 Earnings — Keros Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

KROSKeros Therapeutics, Inc.

$414M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M

Gross Profit

$20M100.0% margin

Operating Income

-$56M-280.5% margin

Net Income

-$59M-292.3% margin

EPS (Diluted)

$-2.52

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$63M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$255M

Total Liabilities

$12M

Stockholders' Equity

$243M

Cash & Equivalents

$230M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$0	—
Gross Profit	$20M	-$605,000	+3422.3%
Operating Income	-$56M	-$47M	-20.8%
Net Income	-$59M	-$45M	-29.5%